Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. Issue 4 (July 2017)

• Record Type: Journal Article
• Authors: Proto, Claudia; Russo, Giuseppe Lo; Corrao, Giulia; Ganzinelli, Monica; Facchinetti, Francesco; Minari, Roberta; Tiseo, Marcello; Garassino, Marina Chiara
• Is Part Of: Tumori. Volume 103:Issue 4(2017)
• Page Start: 325
• Page End: 337
• Publication Date: 2017-07
• Subjects: Epidermal growth factor receptor -- Non-small cell lung cancer -- Resistance mechanisms -- Tyrosine kinase inhibitors; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000663
• Languages: English
• ISSNs: 0300-8916

Abstract

In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) have radically changed the therapeutic management strategies. Currently, erlotinib, gefitinib, and afatinib are all approved as standard first-line treatment in EGFR-mutated NSCLC. However, despite the proven efficacy, some EGFR-mutated NSCLCs do not respond to EGFR TKIs, while some patients, after a favorable and prolonged response to EGFR TKIs, inevitably progress within about 10-14 months. Epidermal growth factor receptor-dependent mechanisms, activation of alternative pathways, or phenotypic transformation can cause the resistance to EGFR TKIs. The exon 20 p.Thr790Met point mutation (T790M) is responsible for about 60% of cases of resistance when progression occurs. A third-generation TKI, osimertinib, improved outcome in patients harboring T790M after first- and second-generation TKI treatment. However, resistance develops even after treatment with third-generation drugs. To date, the Cys797Ser (C797S) mutation in exon 20 of EGFR is the most well-known resistance mutation after osimertinib. Fourth-generation TKIs are already under development. Nevertheless, additional information is needed to better understand and effectively overcome resistance. The aim of this review is to report recent advances and future perspectives in the treatment of EGFR-mutated NSCLC, highlighting the resistance mechanisms that underlie disease progression.